NCT06608784Completed
Comparison Study of Electrocardiogram Indexes in Patients With Epilepsy, Patients With First Seizure and Normal Population
Source: ClinicalTrials.gov · Last updated 23 Sept 2024
Brief summary (registry, in English)
According to recent advances in epileptic heart and sudden unexplained death in epilepsy, in this study the investigators aimed to compare ECG findings in patients with epilepsy, patients who had experienced their first seizure and patients without history of seizure.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 70 (actual)
- First submitted
- 13 Sept 2024
- Start date
- 21 Mar 2023
- Primary completion date
- 21 Mar 2024
- Lead sponsor
- Mazandaran University of Medical Sciences
- Diseases
- Epilepsy
- NCT number
- NCT06608784
What you commit to
- Study type: Observational
- Participants enrolled: 70
- From 21 Mar 2023 to the primary completion date, 21 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Electrolyte imbalance Taking medications with significant effect on ECG indexes
Other illness
- History of known cardiac disease or medical condition precipitating cardiac disease
Who the study is looking for
- History of epilepsy for at least 2 years
- Taking antiseizure medications
- \- Solid history of first seizure confirmed by a neurologist
- \- No history of seizure
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mazandaran University of medical sciences Coordinator of this site? Confirm its status | Sari | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.